{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T09:58:21Z","timestamp":1785491901188,"version":"3.56.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bimekizumab inhibits interleukin-17A and interleukin-17F. Clinical trials have shown its efficacy in moderate-\u00adto-severe plaque psoriasis; however, real-world effectiveness and safety data remain limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the real-world effectiveness and safety of bimekizumab in patients with moderate-to-severe plaque psoriasis over 16 weeks in routine clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a single-centre retrospective observational study involving adults diagnosed with moderate-to-\u00adsevere plaque psoriasis who were administered bimekizumab (320\u2005mg subcutaneously every 4 weeks for 16 weeks). The primary outcomes assessed were \u226590% improvement in Psoriasis Area and Severity Index (PASI 90) and complete clearance (PASI 100) at week 16. Secondary outcomes included \u2265 50% improvement in PASI, \u226575% improvement in PASI, Dermatology Life Quality Index (DLQI) scores and the incidence of adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 86 patients were enrolled. Their mean (SD) age was 44.4 (12.3) years, 53% (n = 46) were women and 58% (n = 50) had prior biologic exposure. At week 16, 71% (n = 61) achieved PASI 90 and 66% (n = 57) achieved PASI 100. By week 4, 50% (n = 43) of the patients had achieved PASI 90. Patients who were biologic-na\u00efve had higher PASI 90 rates than patients who were biologic-experienced (75% vs. 60%; P = 0.08). The complete clearance rates were 71%, 63% and 75% for scalp, nail and genital psoriasis, respectively. The mean (SD) DLQI decreased from 15.8 (6.2) at baseline to 3.2 (2.4) at week 16. Adverse events occurred in 33% of patients (n = 28), most commonly mild oral candidiasis (n = 15; 17%). No serious adverse events or treatment discontinuations were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Bimekizumab demonstrated high efficacy in the real-world treatment of moderate-to-severe plaque psoriasis, with a rapid onset of action and improvement in difficult-to-treat areas. The safety profile was favourable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/skinhd\/vzag060","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T12:50:16Z","timestamp":1774615816000},"page":"496-502","source":"Crossref","is-referenced-by-count":0,"title":["Real-world single-centre experience of bimekizumab in\u00a0patients with psoriasis: a 16-week retrospective observational study"],"prefix":"10.1093","volume":"6","author":[{"given":"Zekayi","family":"Kutlubay","sequence":"first","affiliation":[{"name":"Department of Dermatology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa , Istanbul ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3307-5917","authenticated-orcid":false,"given":"Yusuf","family":"Demir","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa , Istanbul ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurbuz","family":"Yildirim","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa , Istanbul ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bengusu","family":"Yildiz","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa , Istanbul ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma Zehra","family":"Diken","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa , Istanbul ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burhan","family":"Engin","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa , Istanbul ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Server","family":"Serdaroglu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa , Istanbul ,","place":["Turkey"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"key":"2026073105091437900_vzag060-B1","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1111\/bcp.13185","article-title":"First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis","volume":"83","author":"Glatt","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"2026073105091437900_vzag060-B2","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1365-2133.2008.08902.x","article-title":"Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin","volume":"160","author":"Johansen","year":"2009","journal-title":"Br J Dermatol"},{"key":"2026073105091437900_vzag060-B3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/jid.2012.194","article-title":"The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings","volume":"133","author":"Martin","year":"2013","journal-title":"J Invest Dermatol"},{"key":"2026073105091437900_vzag060-B4","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","article-title":"The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis","volume":"55","author":"Blauvelt","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"2026073105091437900_vzag060-B5","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0140-6736(21)00125-2","article-title":"Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"},{"key":"2026073105091437900_vzag060-B6","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa2102388","article-title":"Bimekizumab versus adalimumab in plaque psoriasis","volume":"385","author":"Warren","year":"2021","journal-title":"N Engl J Med"},{"key":"2026073105091437900_vzag060-B7","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus secukinumab in plaque psoriasis","volume":"385","author":"Reich","year":"2021","journal-title":"N Engl J Med"},{"key":"2026073105091437900_vzag060-B8","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/bjd.20827","article-title":"Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double-blind multicentre study","volume":"186","author":"Oliver","year":"2022","journal-title":"Br J Dermatol"},{"key":"2026073105091437900_vzag060-B9","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0140-6736(21)00126-4","article-title":"Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial","volume":"397","author":"Gordon","year":"2021","journal-title":"Lancet"},{"key":"2026073105091437900_vzag060-B10","article-title":"Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study \u2013 IL PSO (Italian landscape psoriasis)","volume":"10","author":"Gargiulo","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"2026073105091437900_vzag060-B11","first-page":"145","article-title":"Real-world experience of bimekizumab in a cohort of 109 patients over 48 weeks and identification of predictive factors for an early super response and risk of adverse events","volume":"15","author":"Fratton","year":"2025","journal-title":"Psoriasis (Auckl)"},{"key":"2026073105091437900_vzag060-B12","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2024.2432932","article-title":"Bimekizumab for the treatment of moderate to severe psoriasis: a real-world experience over 52 weeks from two Italian dermatology clinics","volume":"36","author":"Mortato","year":"2025","journal-title":"J Dermatolog Treat"},{"key":"2026073105091437900_vzag060-B13","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1093\/bjd\/ljac089","article-title":"Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III\/IIIb trials","volume":"188","author":"Kokolakis","year":"2023","journal-title":"Br J Dermatol"},{"key":"2026073105091437900_vzag060-B14","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/ajd.14396","article-title":"Switching within the class of IL-17 inhibitors for the treatment of plaque psoriasis: a real-world retrospective study","volume":"66","author":"Koumprentziotis","year":"2025","journal-title":"Australas J Dermatol"},{"key":"2026073105091437900_vzag060-B15","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1111\/jdv.18409","article-title":"Switches between biologics in patients with moderate-to-severe psoriasis: results from the French cohort PSOBIOTEQ","volume":"36","author":"Curmin","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026073105091437900_vzag060-B16","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1111\/j.1468-3083.2011.04065.x","article-title":"Obesity and psoriasis: body weight and body mass index influence the response to biological treatment","volume":"25","author":"Puig","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026073105091437900_vzag060-B17","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1001\/archderm.143.12.1493","article-title":"The risk of mortality in patients with psoriasis: results from a population-based study","volume":"143","author":"Gelfand","year":"2007","journal-title":"Arch Dermatol"},{"key":"2026073105091437900_vzag060-B18","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.jaad.2016.07.065","article-title":"Psoriasis and comorbid diseases: implications for management","volume":"76","author":"Takeshita","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2026073105091437900_vzag060-B19","doi-asserted-by":"crossref","first-page":"e984","DOI":"10.1161\/CIR.0000000000000973","article-title":"Obesity and cardiovascular disease: a scientific statement from the American Heart Association","volume":"143","author":"Powell-Wiley","year":"2021","journal-title":"Circulation"},{"key":"2026073105091437900_vzag060-B20","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1007\/s00403-025-03818-7","article-title":"Impact of topical and systemic therapy on carotid-intima media thickness in psoriasis","volume":"317","author":"Gumus","year":"2025","journal-title":"Arch Dermatol Res"},{"key":"2026073105091437900_vzag060-B21","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/cvr\/cvz009","article-title":"Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study","volume":"115","author":"Elnabawi","year":"2019","journal-title":"Cardiovasc Res"},{"key":"2026073105091437900_vzag060-B22","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jaad.2025.03.055","article-title":"Association between biologic and nonbiologic systemic therapy for psoriasis and psoriatic arthritis and the risk of new-onset and recurrent major adverse cardiovascular events: a retrospective cohort study","volume":"93","author":"Song","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"2026073105091437900_vzag060-B23","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1007\/s13555-025-01472-5","article-title":"Cardiovascular and kidney outcomes after systemic treatment for plaque psoriasis: a systematic review and network meta-analysis","volume":"15","author":"Shi","year":"2025","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2026073105091437900_vzag060-B24","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1349636","article-title":"Major cardiovascular events under biologic psoriasis therapies: a 19-year real-world analysis of FAERS data","volume":"15","author":"Ding","year":"2024","journal-title":"Front Immunol"},{"key":"2026073105091437900_vzag060-B25","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1007\/s13555-024-01154-8","article-title":"Impact of biologic therapy on key cardiovascular risk parameters in a psoriatic cohort\u2014a retrospective review","volume":"14","author":"Joseph","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2026073105091437900_vzag060-B26","doi-asserted-by":"crossref","first-page":"e361","DOI":"10.1111\/1346-8138.17623","article-title":"A predictive factor of oral candidiasis in psoriasis patients treated with bimekizumab: longer disease duration","volume":"52","author":"Yoneyama","year":"2025","journal-title":"J Dermatol"},{"key":"2026073105091437900_vzag060-B27","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/ijd.17658","article-title":"Bimekizumab treatment for scalp psoriasis: a 52-week, real-world, retrospective study","volume":"64","author":"Stefanaki","year":"2025","journal-title":"Int J Dermatol"},{"key":"2026073105091437900_vzag060-B28","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/1346-8138.17532","article-title":"Effectiveness of long-term bimekizumab treatment and predictive factors for responders in moderate-to-severe psoriasis: a 52-week real-world study","volume":"52","author":"Hagino","year":"2025","journal-title":"J Dermatol"},{"key":"2026073105091437900_vzag060-B29","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1111\/1346-8138.17427","article-title":"Effectiveness of bimekizumab for genital, nail, and scalp lesions with psoriasis: a 24-week real-world study","volume":"51","author":"Hagino","year":"2024","journal-title":"J Dermatol"},{"key":"2026073105091437900_vzag060-B30","first-page":"e297","article-title":"Bimekizumab for the treatment of genital, scalp, and nail psoriasis: a 52-week real-world study","volume":"52","author":"Hagino","year":"2025","journal-title":"J Dermatol"},{"key":"2026073105091437900_vzag060-B31","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12589","article-title":"Underdiagnosed and undertreated psoriasis: nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails","volume":"31","author":"Merola","year":"2018","journal-title":"Dermatol Ther"},{"key":"2026073105091437900_vzag060-B32","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1007\/s13555-024-01295-w","article-title":"Bimekizumab efficacy in high-impact areas: pooled 2-year analysis in scalp, nail, and palmoplantar psoriasis from phase 3\/3b randomized controlled trials","volume":"14","author":"Merola","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2026073105091437900_vzag060-B33","first-page":"iii50","article-title":"The 1-year all-cause drug survival of bimekizumab compared with other biologics in psoriasis: a nationwide real-world cohort study","volume":"191","author":"Schwarz","year":"2024","journal-title":"Br J Dermatol"},{"key":"2026073105091437900_vzag060-B34","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.jaad.2025.04.038","article-title":"Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: results from the BE BRIGHT open-label extension trial","volume":"93","author":"Blauvelt","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"2026073105091437900_vzag060-B35","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2023.2199106","article-title":"Efficacy and safety of bimekizumab for the treatment of psoriasis: a systematic review and meta-analysis of randomized clinical trials","volume":"34","author":"Qiu","year":"2023","journal-title":"J Dermatolog Treat"},{"key":"2026073105091437900_vzag060-B36","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/1346-8138.17186","article-title":"Real-world effectiveness and safety of bimekizumab in Japanese patients with psoriasis: a single-center retrospective study","volume":"51","author":"Hagino","year":"2024","journal-title":"J Dermatol"},{"key":"2026073105091437900_vzag060-B37","first-page":"1","article-title":"Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis","volume":"157","author":"Gisondi","year":"2022","journal-title":"Ital J Dermatol Venerol"},{"key":"2026073105091437900_vzag060-B38","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2026073105091437900_vzag060-B39","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/jdv.16915","article-title":"EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris\u2014part 1: treatment and monitoring recommendations","volume":"34","author":"Nast","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Skin Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/6\/4\/496\/68207693\/vzag060.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/skinhd\/article-pdf\/6\/4\/496\/68207693\/vzag060.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T09:09:24Z","timestamp":1785488964000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/skinhd\/article\/6\/4\/496\/8666947"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":39,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,5,4]]},"published-print":{"date-parts":[[2026,7,31]]}},"URL":"https:\/\/doi.org\/10.1093\/skinhd\/vzag060","relation":{},"ISSN":["2690-442X"],"issn-type":[{"value":"2690-442X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,5,4]]}}}